Publications by authors named "Robert P Kadlec"
Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use.
Disaster Med Public Health Prep
January 2022
Monoclonal antibody therapeutics to treat coronavirus disease (COVID-19) have been authorized by the US Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from 3 sites at medical centers in the United States supported by the National Disaster Medical System.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies (mAbs) show promise in treating COVID-19 by reducing hospitalizations and emergency visits, but their use is limited, especially among disadvantaged groups.
- A study analyzed electronic health records of COVID-19 patients at a medical center, comparing those treated with mAbs to untreated patients from before the treatments were available.
- Results indicated that treated patients had a significantly lower risk (82% less) of hospitalization or emergency visits compared to untreated patients, emphasizing the need for equitable access to mAb treatment across all demographics.
An outbreak of acute gastroenteritis involving 249 persons, 32% of whom were hospitalized, occurred on a U.S. Army installation in 1990.
View Article and Find Full Text PDF